SynthesisBMJ open2014
Treatments for macular oedema following central retinal vein occlusion: systematic review.
Synthesis in BMJ open, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.BMJ open · 2019Pooled it
- Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion.BMC ophthalmology · 2016Pooled it
- Pooled it
- Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.BMJ open · 2014Pooled it
- Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.Health technology assessment (Winchester, England) · 2021Trial
- Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.Japanese journal of ophthalmology · 2017Trial
- Intravitreal Fluocinolone Acetonide Implant (ILUVIENDrug design, development and therapy · 2023Review
- Cost-effectiveness of dexamethasone and triamcinolone for the treatment of diabetic macular oedema in Finland: A Markov-model.Acta ophthalmologica · 2021Article
- Optical coherence tomography angiography.Progress in retinal and eye research · 2018Review
- Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab.BMC ophthalmology · 2018Article
- Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.International ophthalmology · 2018Article
- Central Retinal Vein Occlusion in Younger Swedish Adults: Case Reports and Review of the Literature.The open ophthalmology journal · 2017Article
- Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.Investigative ophthalmology & visual science · 2016Article
- Pivotal clinical trials of novel ophthalmic drugs and medical devices: retrospective observational study, 2002-2012.BMJ open · 2015Observational
- More about retinal disorders.Indian journal of ophthalmology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo review systematically the randomised controlled trial (RCT) evidence for treatment of macular oedema due to central retinal vein occlusion (CRVO). DATA SOURCES: MEDLINE, EMBASE, CDSR, DARE, HTA, NHSEED, CENTRAL and meeting abstracts (January 2005 to March 2013). STUDY ELIGIBILITY CRITERIA, PARTICIPANTS AND
interventionsRCTs with at least 12 months of follow-up assessing pharmacological treatments for CRVO were included with no language restrictions. STUDY APPRAISAL AND SYNTHESIS
methods2 authors screened titles and abstracts and conducted data extracted and Cochrane risk of bias assessment. Meta-analysis was not possible due to lack of comparable studies.
results8 studies (35 articles, 1714 eyes) were included, assessing aflibercept (n=2), triamcinolone (n=2), bevacizumab (n=1), pegaptanib (n=1), dexamethasone (n=1) and ranibizumab (n=1). In general, bevacizumab, ranibizumab, aflibercept and triamcinolone resulted in clinically significant increases in the proportion of participants with an improvement in visual acuity of ≥15 letters, with 40-60% gaining ≥15 letters on active drugs, compared to 12-28% with sham. Results for pegaptanib and dexamethasone were mixed. Steroids were associated with cataract formation and increased intraocular pressure. No overall increase in adverse events was found with bevacizumab, ranibizumab, aflibercept or pegaptanib compared with control. Quality of life was poorly reported. All studies had a low or unclear risk of bias. LIMITATIONS: All studies evaluated a relatively short primary follow-up (1 year or less). Most had an unmasked extension phase. There was no head-to-head evidence. The majority of participants included had non-ischaemic CRVO. CONCLUSIONS AND IMPLICATIONS OF KEY
findingsBevacizumab, ranibizumab, aflibercept and triamcinolone appear to be effective in treating macular oedema secondary to CRVO. Long-term data on effectiveness and safety are needed. Head-to-head trials and research to identify 'responders' is needed to help clinicians make the right choices for their patients. Research aimed to improve sight in people with ischaemic CRVO is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.